Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHIP0804: I-125 prostate brachytherapy with or without adjuvant androgen deprivation in intermediate-risk prostate cancer
jRCTs031180256Phase 3Completed
- Sponsor
- Nihon Medi-Physics Co., Ltd.
- Start
- Apr 2008
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of goserelin and leuprolide in prostate cancer (PCa) (2 arms), sponsored by Nihon Medi-Physics Co., Ltd. Primary endpoint: Biochemical progression-free survival (BPFS). Started Apr 2008; status: completed.
02
Drugs
goserelinleuprolide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCTs031180256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180256.